CTMX vs. LRCX
Compare and contrast key facts about CytomX Therapeutics, Inc. (CTMX) and Lam Research Corporation (LRCX).
Performance
CTMX vs. LRCX - Performance Comparison
Loading graphics...
CTMX vs. LRCX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics, Inc. | 10.33% | 313.59% | -33.55% | -3.13% | -63.05% | -33.89% | -21.18% | -44.97% | -28.47% | 92.08% |
LRCX Lam Research Corporation | 24.97% | 139.16% | -6.84% | 88.63% | -40.72% | 53.66% | 64.18% | 119.33% | -24.40% | 76.21% |
Fundamentals
CTMX:
$799.88M
LRCX:
$270.39B
CTMX:
-$0.11
LRCX:
$4.89
CTMX:
9.55
LRCX:
13.20
CTMX:
8.08
LRCX:
26.65
CTMX:
$76.20M
LRCX:
$20.56B
CTMX:
$75.69M
LRCX:
$10.24B
CTMX:
-$19.39M
LRCX:
$7.43B
Returns By Period
In the year-to-date period, CTMX achieves a 10.33% return, which is significantly lower than LRCX's 24.97% return. Over the past 10 years, CTMX has underperformed LRCX with an annualized return of -9.91%, while LRCX has yielded a comparatively higher 40.32% annualized return.
CTMX
- 1D
- 6.58%
- 1M
- -12.48%
- YTD
- 10.33%
- 6M
- 47.34%
- 1Y
- 639.23%
- 3Y*
- 46.01%
- 5Y*
- -9.80%
- 10Y*
- -9.91%
LRCX
- 1D
- 6.87%
- 1M
- -8.54%
- YTD
- 24.97%
- 6M
- 60.02%
- 1Y
- 196.05%
- 3Y*
- 60.68%
- 5Y*
- 28.66%
- 10Y*
- 40.32%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CTMX vs. LRCX — Risk / Return Rank
CTMX
LRCX
CTMX vs. LRCX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CytomX Therapeutics, Inc. (CTMX) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CTMX | LRCX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.81 | 3.67 | +0.14 |
Sortino ratioReturn per unit of downside risk | 4.71 | 3.58 | +1.12 |
Omega ratioGain probability vs. loss probability | 1.61 | 1.50 | +0.11 |
Calmar ratioReturn relative to maximum drawdown | 15.76 | 9.82 | +5.94 |
Martin ratioReturn relative to average drawdown | 36.65 | 31.04 | +5.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| CTMX | LRCX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.81 | 3.67 | +0.14 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.07 | 0.63 | -0.70 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.09 | 0.92 | -1.01 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.08 | 0.41 | -0.49 |
Correlation
The correlation between CTMX and LRCX is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
CTMX vs. LRCX - Dividend Comparison
CTMX has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.47%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTMX CytomX Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LRCX Lam Research Corporation | 0.47% | 0.57% | 1.19% | 0.95% | 1.53% | 0.78% | 1.04% | 1.54% | 2.79% | 1.01% | 1.28% | 1.36% |
Drawdowns
CTMX vs. LRCX - Drawdown Comparison
The maximum CTMX drawdown since its inception was -98.74%, which is greater than LRCX's maximum drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for CTMX and LRCX.
Loading graphics...
Drawdown Indicators
| CTMX | LRCX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.74% | -87.90% | -10.84% |
Max Drawdown (1Y)Largest decline over 1 year | -41.14% | -20.01% | -21.13% |
Max Drawdown (5Y)Largest decline over 5 years | -95.65% | -56.39% | -39.26% |
Max Drawdown (10Y)Largest decline over 10 years | -98.74% | -56.39% | -42.35% |
Current DrawdownCurrent decline from peak | -86.27% | -14.26% | -72.01% |
Average DrawdownAverage peak-to-trough decline | -70.40% | -28.31% | -42.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.69% | 6.33% | +11.36% |
Volatility
CTMX vs. LRCX - Volatility Comparison
CytomX Therapeutics, Inc. (CTMX) has a higher volatility of 53.47% compared to Lam Research Corporation (LRCX) at 20.58%. This indicates that CTMX's price experiences larger fluctuations and is considered to be riskier than LRCX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| CTMX | LRCX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 53.47% | 20.58% | +32.89% |
Volatility (6M)Calculated over the trailing 6-month period | 74.27% | 40.44% | +33.83% |
Volatility (1Y)Calculated over the trailing 1-year period | 169.33% | 53.75% | +115.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 142.15% | 45.53% | +96.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.35% | 44.09% | +67.26% |
Financials
CTMX vs. LRCX - Financials Comparison
This section allows you to compare key financial metrics between CytomX Therapeutics, Inc. and Lam Research Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities